Monocyte chemotactic protein‐1 (MCP‐1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia
- 9 November 2009
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 70 (5) , 473-481
Abstract
BACKGROUND: Chronic inflammation is commonly observed in benign prostate hyperplasia (BPH), and prostate tissue often contains increased inflammatory infiltrates, including T cells and macrophages. Cytokines are not only key mediators of inflammation but may also play important roles in the initiation and progression of BPH.METHODS: In order to determine what cytokines might be involved in prostatic enlargement, expressed prostatic secretions (EPS) from ex vivo prostates were analyzed by human cytokine antibody microarray and ELISA. Prostate epithelial cells (PrEC) and prostate stromal cells (PrSC) were used for ELISA, proliferation, and Western blot assays.RESULTS: Monocyte chemotactic protein‐1 (MCP‐1/CCL2) was one of the most elevated proteins in secretions from large prostate glands. PrSC were found to secrete MCP‐1; Western blotting showed that both PrSC and PrEC express the MCP‐1 receptor CCR2 which by RT‐PCR was the CCR2b isoform. Proliferation assays showed that MCP‐1 stimulates the proliferation of PrEC, but not PrSC, and that a specific MCP‐1 antagonist (RS102895) suppressed this effect. Conditioned medium from PrSC stimulated the proliferation of PrEC as well, an effect completely inhibited by both RS102895 and a neutralizing anti‐MCP‐1 monoclonal antibody. The inflammatory cytokines interleukin (IL)‐1β, interferon‐γ, and IL‐2 enhanced the secretion of MCP‐1 from PrEC and PrSC. In addition, MCP‐1 levels in EPS correlated with mRNA levels of the macrophage marker CD68 in the same secretions.CONCLUSIONS: The cytokine MCP‐1, of apparent prostatic stromal cell origin, may play an important role in prostatic enlargement and BPH, and is a candidate biomarker for these pathologic processes. Prostate 70: 473–481, 2010.Keywords
Funding Information
- NIH/NIDDK (1K23DK071262)
- Department of Defense (W81XWH-05-0167)
This publication has 34 references indexed in Scilit:
- A Destructive Cascade Mediated by CCL2 Facilitates Prostate Cancer Growth in BoneCancer Research, 2009
- Monocyte Chemoattractant Protein-1 and Macrophage Inflammatory Protein-1α as Possible Biomarkers for the Chronic Pelvic Pain SyndromeJournal of Urology, 2008
- Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammationThe Prostate, 2008
- Cellular and molecular mechanisms of fibrosisThe Journal of Pathology, 2007
- CCL2 is a Potent Regulator of Prostate Cancer Cell Migration and ProliferationNeoplasia, 2006
- Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasionThe Prostate, 2006
- Correlation Of Minute (0.5 MM or Less) Focus of Prostate Adenocarcinoma On Needle Biopsy With Radical Prostatectomy Specimen: Role of Prostate Specific Antigen DensityJournal of Urology, 2003
- Monocyte Chemoattractant Protein‐1 (CCL2) in Inflammatory Disease and Adaptive Immunity: Therapeutic Opportunities and ControversiesMicrocirculation, 2003
- Monocyte Chemoattractant Protein-1 (CCL2) in Inflammatory Disease and Adaptive Immunity: Therapeutic Opportunities and ControversiesMicrocirculation, 2003
- Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes.Journal of Clinical Investigation, 1995